Published in Infect Immun on February 13, 2012
High avidity antibodies to full-length VAR2CSA correlate with absence of placental malaria. PLoS One (2012) 1.09
Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell Mol Life Sci (2014) 1.03
Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin. Emerg Infect Dis (2015) 0.96
Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria. Infect Immun (2012) 0.94
The antibody response of pregnant Cameroonian women to VAR2CSA ID1-ID2a, a small recombinant protein containing the CSA-binding site. PLoS One (2014) 0.92
Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA. PLoS One (2014) 0.86
The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. PLoS One (2015) 0.85
Parity-dependent recognition of DBL1X-3X suggests an important role of the VAR2CSA high-affinity CSA-binding region in the development of the humoral response against placental malaria. Infect Immun (2015) 0.84
Comparison of the specificity of antibodies to VAR2CSA in Cameroonian multigravidae with and without placental malaria: a retrospective case-control study. Malar J (2015) 0.83
Identification of VAR2CSA domain-specific inhibitory antibodies of the Plasmodium falciparum erythrocyte membrane protein 1 using a novel flow cytometry assay. Clin Vaccine Immunol (2013) 0.83
Antigen reversal identifies targets of opsonizing IgGs against pregnancy-associated malaria. Infect Immun (2014) 0.83
Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine (2015) 0.80
Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology (2015) 0.80
Influence of Intermittent Preventive Treatment on Antibodies to VAR2CSA in Pregnant Cameroonian Women. Am J Trop Med Hyg (2015) 0.79
New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. Genome Med (2017) 0.78
Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women. Am J Trop Med Hyg (2015) 0.78
Plasmodium falciparum variability and immune evasion proceed from antigenicity of consensus sequences from DBL6ε; generalization to all DBL from VAR2CSA. PLoS One (2013) 0.77
Antibody recognition of Plasmodium falciparum infected red blood cells by symptomatic and asymptomatic individuals in the Brazilian Amazon. Mem Inst Oswaldo Cruz (2014) 0.76
Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation. Malar J (2016) 0.75
Usefulness of a biomarker to identify placental dysfunction in the context of malaria. Malar J (2017) 0.75
Antibody responses to the full-length VAR2CSA and its DBL domains in Cameroonian children and teenagers. Malar J (2016) 0.75
Maternal Human Immunodeficiency Virus-Associated Hypergammaglobulinemia Reduces Transplacental Transfer of Immunoglobulin G to Plasmodium falciparum Antigens in Cameroonian Neonates. Open Forum Infect Dis (2016) 0.75
Multiplexing detection of IgG against Plasmodium falciparum pregnancy-specific antigens. PLoS One (2017) 0.75
Statistical prediction of immunity to placental malaria based on multi-assay antibody data for malarial antigens. Malar J (2017) 0.75
Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet (2010) 26.48
The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med (1985) 12.23
An analysis of malaria in pregnancy in Africa. Bull World Health Organ (1983) 6.09
Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol (2003) 6.04
Maternal antibodies block malaria. Nature (1998) 5.67
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med (2004) 4.76
Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop Med Hyg (1983) 3.46
Epidemiology, malaria and pregnancy. Am J Trop Med Hyg (1984) 3.32
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
The sick placenta-the role of malaria. Placenta (2004) 3.18
Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun (2003) 3.05
A family affair: var genes, PfEMP1 binding, and malaria disease. Curr Opin Microbiol (2006) 2.93
Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. Malar J (2010) 2.73
Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis (2008) 2.69
Recombination hotspots and population structure in Plasmodium falciparum. PLoS Biol (2005) 2.67
Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Mol Biochem Parasitol (2006) 2.24
Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg (2002) 2.03
Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA. Mol Biochem Parasitol (2007) 1.86
Gravidity-dependent production of antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to placental chondroitin sulfate proteoglycan during pregnancy. Infect Immun (2001) 1.82
Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun (2009) 1.65
Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. J Infect Dis (2004) 1.63
Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS Pathog (2008) 1.60
Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. Clin Vaccine Immunol (2006) 1.55
The effect of timing and frequency of Plasmodium falciparum infection during pregnancy on the risk of low birth weight and maternal anemia. Trans R Soc Trop Med Hyg (2010) 1.49
Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol (2006) 1.48
Structure of the DBL3x domain of pregnancy-associated malaria protein VAR2CSA complexed with chondroitin sulfate A. Nat Struct Mol Biol (2008) 1.48
Impact of malaria at the end of pregnancy on infant mortality and morbidity. J Infect Dis (2011) 1.45
Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. Exp Parasitol (2006) 1.44
Dynamics of anti-VAR2CSA immunoglobulin G response in a cohort of senegalese pregnant women. J Infect Dis (2006) 1.43
Ex vivo desequestration of Plasmodium falciparum-infected erythrocytes from human placenta by chondroitin sulfate A. Infect Immun (1999) 1.29
Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA. Infect Immun (2008) 1.29
Antibodies among men and children to placental-binding Plasmodium falciparum-infected erythrocytes that express var2csa. Am J Trop Med Hyg (2007) 1.21
The impact of maternal malaria on newborns. Ann Trop Paediatr (2010) 1.21
Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. Am J Pathol (2004) 1.19
Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes. Infect Immun (2010) 1.18
Fetal origins of adult diabetes. Ann N Y Acad Sci (2010) 1.08
Chondroitin sulfate A-adhering Plasmodium falciparum-infected erythrocytes express functionally important antibody epitopes shared by multiple variants. J Immunol (2010) 1.08
Longitudinal studies of Plasmodium falciparum malaria in pregnant women living in a rural Cameroonian village with high perennial transmission. Am J Trop Med Hyg (2010) 1.06
Cytoadherence of Plasmodium falciparum-infected erythrocytes in the human placenta. Parasite Immunol (2000) 1.05
Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics and protection during pregnancy in women receiving intermittent preventive treatment. J Infect Dis (2010) 1.04
Low birth weight and risk of affective disorders and selected medical illness in offspring at high and low risk for depression. Compr Psychiatry (2007) 0.95
Association of low birth weight and placental malarial infection in Nigeria. J Infect Dev Ctries (2009) 0.94
Behavioural and emotional outcome of very low birth weight infants--literature review. J Matern Fetal Neonatal Med (2009) 0.94
Optimizing expression of the pregnancy malaria vaccine candidate, VAR2CSA in Pichia pastoris. Malar J (2009) 0.91
Induction of strain-transcendent antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins. Malar J (2011) 0.91
Chondroitin sulfate proteoglycan expression and binding of Plasmodium falciparum-infected erythrocytes in the human placenta during pregnancy. Infect Immun (2003) 0.91
Acquisition of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes during pregnancy. Infect Genet Evol (2006) 0.90
The contribution of very low birth weight deaths to infant mortality. East Afr Med J (2009) 0.87
Positive selection of Plasmodium falciparum parasites with multiple var2csa-type PfEMP1 genes during the course of infection in pregnant women. J Infect Dis (2011) 0.87
Analysis of IgG with specificity for variant surface antigens expressed by placental Plasmodium falciparum isolates. Malar J (2004) 0.86
Placental malaria, anaemia and low birthweight in Yemen. Trans R Soc Trop Med Hyg (2009) 0.86
Variant antigens of Plasmodium falciparum encoded by the var multigenic family are multifunctional macromolecules. Res Microbiol (2001) 0.79
Quantitative computer image analysis of chondroitin sulfate A expression in placentas infected with Plasmodium falciparum. J Histochem Cytochem (1999) 0.78
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun (2002) 4.02
Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis (2007) 3.88
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun (2005) 3.72
Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J Exp Med (2004) 3.63
Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding regions. Malar J (2003) 3.57
Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun (2002) 3.08
A family affair: var genes, PfEMP1 binding, and malaria disease. Curr Opin Microbiol (2006) 2.93
Evidence for the importance of genetic structuring to the structural and functional specialization of the Plasmodium falciparum var gene family. Mol Microbiol (2003) 2.92
Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine (2007) 2.88
Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature (2013) 2.86
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
Widespread functional specialization of Plasmodium falciparum erythrocyte membrane protein 1 family members to bind CD36 analysed across a parasite genome. Mol Microbiol (2003) 2.46
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Mol Biochem Parasitol (2006) 2.24
Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. J Infect Dis (2005) 2.24
Patterns of gene recombination shape var gene repertoires in Plasmodium falciparum: comparisons of geographically diverse isolates. BMC Genomics (2007) 2.23
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine (2005) 2.21
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
Traumatic events and symptoms of post-traumatic stress disorder amongst Sudanese nationals, refugees and Ugandans in the West Nile. Afr Health Sci (2004) 2.03
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun (2006) 2.02
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther (2011) 1.92
High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. J Infect Dis (2005) 1.90
A restricted subset of var genes mediates adherence of Plasmodium falciparum-infected erythrocytes to brain endothelial cells. Proc Natl Acad Sci U S A (2012) 1.90
Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA. Mol Biochem Parasitol (2007) 1.86
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One (2008) 1.81
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog (2006) 1.76
Effective induction of high-titer antibodies by viral vector vaccines. Nat Med (2008) 1.76
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther (2012) 1.76
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A (2006) 1.74
A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci U S A (2001) 1.71
Sequential, ordered acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 domains. J Immunol (2009) 1.66
Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun (2003) 1.65
Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun (2009) 1.65
Malaria in pregnant Cameroonian women: the effect of age and gravidity on submicroscopic and mixed-species infections and multiple parasite genotypes. Am J Trop Med Hyg (2005) 1.62
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One (2007) 1.60
Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect Dis (2003) 1.60
Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS Pathog (2008) 1.60
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials (2007) 1.58
Antigenic variation in Plasmodium falciparum: gene organization and regulation of the var multigene family. Eukaryot Cell (2007) 1.58
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One (2012) 1.58
Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies. J Mol Biol (2010) 1.56
Malaria vectors and transmission dynamics in coastal south-western Cameroon. Malar J (2007) 1.54
Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis (2002) 1.53
Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes. Infect Immun (2006) 1.53
Investigating the host binding signature on the Plasmodium falciparum PfEMP1 protein family. PLoS Pathog (2011) 1.53
Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. J Biol Chem (2012) 1.52
Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol (2006) 1.48
Expression of Plasmodium falciparum erythrocyte membrane protein 1 in experimentally infected humans. Malar J (2005) 1.48
Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One (2008) 1.47
Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol (2009) 1.46
Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog (2012) 1.43
Mapping a common interaction site used by Plasmodium falciparum Duffy binding-like domains to bind diverse host receptors. Mol Microbiol (2007) 1.42
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun (2009) 1.39
Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma? Int J Gynecol Cancer (2015) 1.39
The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains. J Biol Chem (2011) 1.36
VAR2CSA expression on the surface of placenta-derived Plasmodium falciparum-infected erythrocytes. J Infect Dis (2008) 1.34
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol (2008) 1.34
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine (2006) 1.33
Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun (2006) 1.32
Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg (2006) 1.30
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis (2013) 1.30
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J (2007) 1.29
Disruption of var2csa gene impairs placental malaria associated adhesion phenotype. PLoS One (2007) 1.29
Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA. Infect Immun (2008) 1.29
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine (2007) 1.28
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One (2011) 1.27
Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Emerg Infect Dis (2013) 1.26
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One (2010) 1.25
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One (2011) 1.25
Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine (2005) 1.25
Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One (2011) 1.22
Identification of a 67-amino-acid region of the Plasmodium falciparum variant surface antigen that binds chondroitin sulphate A and elicits antibodies reactive with the surface of placental isolates. Mol Microbiol (2004) 1.22
Severe malaria in Cameroonian children: correlation between plasma levels of three soluble inducible adhesion molecules and TNF-alpha. Acta Trop (2007) 1.20
VAR2CSA domains expressed in Escherichia coli induce cross-reactive antibodies to native protein. J Infect Dis (2008) 1.20
Chondroitin sulphate A (CSA)-binding of single recombinant Duffy-binding-like domains is not restricted to Plasmodium falciparum Erythrocyte Membrane Protein 1 expressed by CSA-binding parasites. Int J Parasitol (2009) 1.19
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine (2009) 1.19
Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. Am J Pathol (2004) 1.19
Plasmodium falciparum: VAR2CSA expressed during pregnancy-associated malaria is partially resistant to proteolytic cleavage by trypsin. Exp Parasitol (2007) 1.18
Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes. Infect Immun (2010) 1.18
High efficacy of anti DBL4ɛ-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine (2010) 1.18
The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine (2010) 1.17
Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine. Proc Natl Acad Sci U S A (2011) 1.17
Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun (2010) 1.15
Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol (2008) 1.15
In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun (2007) 1.15
Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS One (2013) 1.13
Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis (2003) 1.12
Measurement of HIV prevention indicators: a comparison of the PLACE method and a household survey in Zambia. AIDS Behav (2008) 1.12
Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods (2007) 1.11
Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun (2011) 1.11